Showing results (311-320 of 889) with videos related to
Sort By:
Pageof 89
Drugs in R&D|April 9, 2005
Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary findingsF J Martin, K Melnik, T West, et al.Drugs in R&D|December 22, 2007
Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndromeNicholas L Meyers, Roger I HicklingDrugs in R&D|November 19, 2024
In-Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature ConditionsRoman Borišek, André Mischo, Tobias FoierlDrugs in R&D|October 5, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese ParticipantsShan Jing, Yu Zhang, Yang Lin, et al.Drugs in R&D|October 21, 2024
Pharmacokinetics and Bioequivalence of Two Powders of Azithromycin for Suspension: A Nonblinded, Single-Dose, Randomized, Three-Way Crossover Study in Fed and Fasting States Among Healthy Chinese VolunteersJunbo Shao, Xingxing Liu, Jing Lin, et al.Drugs in R&D|September 24, 2024
Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid LeukemiaMathieu Quesnel-Vallières, David C Schultz, Alena Orlenko, et al.Drugs in R&D|September 18, 2024
A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic LesionsLi Tang, Hongjian Shi, Weijun Liu, et al.Drugs in R&D|October 29, 2024
Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I StudyCaiyun Jia, Na Zhao, Haojing Song, et al.Pageof 89